Fibroblast Specific Inhibition of LOXL2 and TGFbeta1 Signaling in Patients With Pulmonary Fibrosis.
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
This is a two part study. In the first part, the pharmacokinetic profile of
Epigallocatechin-3-gallate (EGCG) in normal human volunteers given a single oral dose will be
determined to set the dose for the second part of the study. In the second part of this
study, lung biopsy fragments and urine samples from patients with interstitial lung disease
treated with EGCG will be evaluated in biochemical assays and compared to samples from
untreated control patients.